CYP51A1 and Chagas disease: cruzi chemotherapy is challenged by mutations such as those in the genes encoding CYP51 or mitochondrial nitroreductase (TcNTR-1) in parasites, contributing to Chagas disease therapy failure (Campos et al., 2017).